• 1
    Piccart MJ,Floquet A,Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003; 13(suppl 2): 196203.
  • 2
    Karlan By,Markamn MA,Eifel PJ. Ovarian cancer peritoneal carcinoma and fallopian tube carcinoma. In: De Vita,Hellman,Rosemberg, eds. Cancer: Principles and Practice of Oncology.7th Edition. Philadelphia: Lippincott Williams and Wilkins; 2005.
  • 3
    Vasey PA,Jayson GC,Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96: 16821691.
  • 4
    Diaz-Montes TP,Bristow RE. Secondary cytoreduction for patients with recurrent ovarian cancer [review]. Curr Oncol Rep. 2005; 7: 451458.
  • 5
    Santillan A,Karam AK,Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007; 104: 686690.
  • 6
    Griffith CT. Surgical resections of tumour bulk in the primary treatment of ovarian carcinoma. NCI Monogr. 1975; 42: 101104.
  • 7
    Hoskins WJ,McGuire WP,Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994; 170: 974979; discussion, 979–980.
  • 8
    Eisenkop SM,Friedman RL,Wang HJ, et al. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998; 69: 103108.
  • 9
    Bristow RE,Tomacruz RS,Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20: 12481259.
  • 10
    Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J Clin Oncol. 2007; 25: 41684170.
  • 11
    Eisenkop SM,Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with biological aggressiveness and survival? Gynecol Oncol. 2001; 82: 436441.
  • 12
    Aletti G,Dowdy SC,Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006; 107: 7785.
  • 13
    Chi DS,Franklin CC,DAAkselrod F, et al. Improved optimal cytoreduction rates for stages III C and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a chance in surgical approach. Gynecol Oncol. 2004; 94: 650654.
  • 14
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221: 2942.
  • 15
    Sugarbaker PM,Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999; 6: 727731.
  • 16
    Glehen O,Kwiatkowski F,Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004; 22: 32843292.
  • 17
    Look M,Chang D,Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004; 14: 3541.
  • 18
    Zanon C,Clara R,Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004; 28: 10401045.
  • 19
    Piso P,Dahlke MH,Loss M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol. 2004; 2: 21.
  • 20
    Reichman TW,Cracchiolo B,Sama J, et al. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol. 2005; 90: 5158.
  • 21
    Rufian S,Munoz-Casares FC,Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006; 94: 316324.
  • 22
    Raspagliesi F,Kusamura S,Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006; 32: 671675.
  • 23
    Cotte E,Glemen O,Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007; 31: 18131820.
  • 24
    Helm CW,Randall-Whitis L,Martin RS, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 2007; 105: 9096.
  • 25
    World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO; 1979.
  • 26
    Jacquet P,Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: SugarbakerPH, editor. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic; 1996: 359374.
  • 27
    SugarbakerPH, editor. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic; 1996.
  • 28
    Bozzetti F,Braga M,Gianotti L, et al. Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet. 2001; 358: 14871492.
  • 29
    AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors. 6th ed. Berlin: Springer; 2002.
  • 30
    Sugarbaker PH. Commentary:Reichman TW, et al. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol. 2005; 90: 5658.
  • 31
    Bristow RE,Duska LR,Lambrou NC, et al. A model for prediction surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000; 89: 15321540.
  • 32
    Berchuck A,Iversen S,Lancaster J, et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use microarrays. Am J Obstet Gynecol. 2004; 190: 910925.
  • 33
    Angioli R,Paldia I,Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006; 100: 455461.
  • 34
    Eisenkop SM,Spirtos NM,Friedman RL, et al. Relative influences of tumour before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003; 90: 390396.
  • 35
    Zang RY,Li ZT,Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004; 100: 11521161.
  • 36
    Scholz HS,Tasdemir H,Hunlich T, et al. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol. 2007; 106: 591595.
  • 37
    Magtibay PM,Adams PB,Silverman MB, et al. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2006; 102: 369374.
  • 38
    Merideth MA,Cliby WA,Keeney GL, et al. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003; 89: 1621.
  • 39
    Chi DS,Eisenhauer EL,Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006; 103: 559564.